$ADVM
Adverum Biotechnologies, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515185889 Filed on May 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $203.0K $203.0K $30.00K
YoY Change 50.37% 576.67% -90.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.960M $4.140M $730.0K
YoY Change 232.89% 467.12% 421.43%
% of Gross Profit
Research & Development $5.126M $5.621M $910.0K
YoY Change 65.68% 517.69% 355.0%
% of Gross Profit
Depreciation & Amortization $150.0K $120.0K $10.00K
YoY Change 650.0% 1100.0%
% of Gross Profit
Operating Expenses $10.09M $9.764M $1.636M
YoY Change 119.81% 496.82% 378.36%
Operating Profit -$9.882M -$9.561M -$1.606M
YoY Change 121.92% 495.33%
Interest Expense $0.00 $0.00 $14.00K
YoY Change -100.0% -100.0% -240.0%
% of Operating Profit
Other Income/Expense, Net $116.0K $52.00K -$57.00K
YoY Change -118.1% -191.23% -670.0%
Pretax Income -$9.770M -$9.510M -$1.660M
YoY Change 91.94% 472.89% 3220.0%
Income Tax
% Of Pretax Income
Net Earnings -$9.766M -$9.509M -$1.663M
YoY Change 91.72% 471.8% 3293.88%
Net Earnings / Revenue -4810.84% -4684.24% -5543.33%
Basic Earnings Per Share
Diluted Earnings Per Share -$382.2K -$382.1K -$77.72K
COMMON SHARES
Basic Shares Outstanding 25.53M shares 25.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $279.6M $290.1M $200.0K
YoY Change 433.59% 144950.0%
Cash & Equivalents $200.5M $201.8M $169.0K
Short-Term Investments $79.10M $88.30M
Other Short-Term Assets $1.000M $1.000M $400.0K
YoY Change 100.0% 150.0%
Inventory
Prepaid Expenses
Receivables $200.0K
Other Receivables $0.00
Total Short-Term Assets $280.6M $291.1M $800.0K
YoY Change 430.46% 36291.5%
LONG-TERM ASSETS
Property, Plant & Equipment $2.945M $1.421M $100.0K
YoY Change 478.59% 1321.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $138.0K $138.0K $200.0K
YoY Change -89.97% -31.0%
Total Long-Term Assets $3.083M $1.559M $300.0K
YoY Change 63.55% 419.67%
TOTAL ASSETS
Total Short-Term Assets $280.6M $291.1M $800.0K
Total Long-Term Assets $3.083M $1.559M $300.0K
Total Assets $283.7M $292.7M $1.100M
YoY Change 417.83% 26508.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.896M $2.787M $900.0K
YoY Change 20.3% 209.67%
Accrued Expenses $3.600M $2.500M $700.0K
YoY Change 125.0% 257.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.864M $7.628M $1.600M
YoY Change 97.04% 376.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $5.200M $5.400M $100.0K
YoY Change -27.78% 5300.0%
Total Long-Term Liabilities $5.200M $5.400M $200.0K
YoY Change -33.33% 2600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.864M $7.628M $1.600M
Total Long-Term Liabilities $5.200M $5.400M $200.0K
Total Liabilities $13.09M $13.01M $1.800M
YoY Change 11.39% 622.83%
SHAREHOLDERS EQUITY
Retained Earnings -$55.99M -$46.22M
YoY Change 209.87%
Common Stock $326.6M $325.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $270.6M $279.7M -$700.0K
YoY Change
Total Liabilities & Shareholders Equity $283.7M $292.7M $1.100M
YoY Change 417.83% 26508.27%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$9.766M -$9.509M -$1.663M
YoY Change 91.72% 471.8% 3293.88%
Depreciation, Depletion And Amortization $150.0K $120.0K $10.00K
YoY Change 650.0% 1100.0%
Cash From Operating Activities -$9.250M -$7.740M -$1.350M
YoY Change -261.43% 473.33% 864.29%
INVESTING ACTIVITIES
Capital Expenditures -$1.080M $411.0K $47.00K
YoY Change 157.14% 774.47% -158.75%
Acquisitions
YoY Change
Other Investing Activities $8.900M -$88.37M
YoY Change
Cash From Investing Activities $7.830M -$88.78M -$50.00K
YoY Change -1964.29% 177460.0% -37.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.300M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 110.0K 139.0M 1.000M
YoY Change -99.77% 13798.0% 233.33%
NET CHANGE
Cash From Operating Activities -9.250M -7.740M -1.350M
Cash From Investing Activities 7.830M -88.78M -50.00K
Cash From Financing Activities 110.0K 139.0M 1.000M
Net Change In Cash -1.310M 42.46M -400.0K
YoY Change -102.51% -10715.0% -600.0%
FREE CASH FLOW
Cash From Operating Activities -$9.250M -$7.740M -$1.350M
Capital Expenditures -$1.080M $411.0K $47.00K
Free Cash Flow -$8.170M -$8.151M -$1.397M
YoY Change -232.85% 483.46% 2228.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25528922 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25473938 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25473938 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2528000
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4943000
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
308000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7628000
CY2015Q1 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2787000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46224000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
325934000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
279680000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
43000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
292691000
CY2015Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1185000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2313000
CY2015Q1 us-gaap Liabilities
Liabilities
13011000
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
440000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
CY2015Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
888000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
201849000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18600000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1421000
CY2015Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
269763000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1007000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
36000
CY2015Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
88276000
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1729000
CY2015Q1 us-gaap Assets
Assets
292691000
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
181487000
CY2015Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
88276000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
138000
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
88311000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
230000 shares
CY2015Q1 us-gaap Assets Current
AssetsCurrent
291132000
CY2015Q1 aavl Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
181487000
CY2015Q1 aavl Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
412000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
564000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22754037 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22754037 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0 Securities
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3707000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6646000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
190000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5471000
CY2014Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
951000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36715000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
186186000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
149483000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
20000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
161906000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1236000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
813000
CY2014Q4 us-gaap Liabilities
Liabilities
12423000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
306000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1509000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159404000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1085000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
40000000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
874000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1275000
CY2014Q4 us-gaap Assets
Assets
161906000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
543000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
160278000
CY2014Q4 aavl Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
942000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8300000
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
115000
CY2014Q1 us-gaap Interest Expense
InterestExpense
14000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
1636000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
910000
CY2014Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
14000
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
25000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.93
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1347000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018 pure
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3673000 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.78 pure
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8377000 shares
CY2014Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
30000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
150000
CY2014Q1 us-gaap Straight Line Rent
StraightLineRent
-69000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1606000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1663000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-1663000
CY2014Q1 us-gaap Interest Paid
InterestPaid
5000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
225000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-395000
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
37000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1000000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
269000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-47000
CY2014Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1000000
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
726000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
178000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
115000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2014Q1 aavl Deferred Offering Costs Accrued Expenses
DeferredOfferingCostsAccruedExpenses
46000
CY2014Q1 aavl Warrants Issued In Connection With License Agreement
WarrantsIssuedInConnectionWithLicenseAgreement
41000
CY2015Q1 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0 Claims
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Avalanche Biotechnologies, Inc.
CY2015Q1 dei Trading Symbol
TradingSymbol
AAVL
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
34.00
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2015Q1 us-gaap Maturities Of Time Deposits Description
MaturitiesOfTimeDepositsDescription
Less than one year
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7742000
CY2015Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>Reclassifications</b>&#x2014;The Company has reclassified certain prior period amounts to conform to the current period presentation. The Company reclassified changes in fair value of warrant liabilities from other income (expense), net and presented it as a separate line item on the condensed consolidated statements of operations and comprehensive loss. The reclassification had no impact on the total income (expense), net or net loss.</p> </div>
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018 pure
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24887000 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001501756
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.78 pure
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4952000 shares
CY2015Q1 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
CY2015Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
88370000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
411000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9509000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
773000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-203000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
9764000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5621000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
42445000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
118000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-59000
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2015Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-35000
CY2015Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
203000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
120000
CY2015Q1 us-gaap Straight Line Rent
StraightLineRent
-134000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9561000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9552000
CY2015Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
52000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
CY2015Q1 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
138975000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
138954000
CY2015Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-1000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-764000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-88781000
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-7000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4143000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1771000
CY2015Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
773000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4400000
CY2015Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2015Q1 aavl Share Based Compensation Arrangement By Share Based Payment Award Options Difference Between Options Exercise Price And Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDifferenceBetweenOptionsExercisePriceAndClosingPriceOfCommonStockIntrinsicValueAmount
40.52
CY2015Q1 aavl Fixed Assets In Accounts Payable And Accrued Liabilities
FixedAssetsInAccountsPayableAndAccruedLiabilities
278000

Files In Submission

Name View Source Status
0001193125-15-185889-index-headers.html Edgar Link pending
0001193125-15-185889-index.html Edgar Link pending
0001193125-15-185889.txt Edgar Link pending
0001193125-15-185889-xbrl.zip Edgar Link pending
aavl-20150331.xml Edgar Link completed
aavl-20150331.xsd Edgar Link pending
aavl-20150331_cal.xml Edgar Link unprocessable
aavl-20150331_def.xml Edgar Link unprocessable
aavl-20150331_lab.xml Edgar Link unprocessable
aavl-20150331_pre.xml Edgar Link unprocessable
d899504d10q.htm Edgar Link pending
d899504dex311.htm Edgar Link pending
d899504dex312.htm Edgar Link pending
d899504dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending